Ontology Browser

Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Warnings and Precautions ALYMS

Annotations (1)

rdfs:comment "Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ (5.1) Surgery and Wound Healing Complications: In patients who experience wound healing complications during Alymsys treatment, withhold Alymsys until adequate wound healing. Withhold for at least 28 days prior to elective surgery. Do not administer Alymsys for at least 28 days following a major surgery, and until adequate wound healing. The safety of resumption of bevacizumab products after resolution of wound healing complication has not been established. Discontinue for wound healing complication of necrotizing fasciitis. (5.2) Hemorrhage: Severe or fatal hemorrhages have occurred. Do not administer for recent hemoptysis. Discontinue for Grade 3-4 hemorrhage (5.3) Arterial Thromboembolic Events (ATE): Discontinue for severe ATE. (5.4) Venous Thromboembolic Events (VTE): Discontinue for Grade 4 VTE. (5.5) Hypertension: Monitor blood pressure and treat hypertension. Withhold if not medically controlled; resume once controlled. Discontinue for hypertensive crisis or hypertensive encephalopathy. (5.6) Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue. (5.7) Renal Injury and Proteinuria: Monitor urine protein. Discontinue for nephrotic syndrome. Withhold until less than 2 grams of protein in urine. (5.8) Infusion-Related Reactions: Decrease rate for infusionrelated reactions. Discontinue for severe infusion-related reactions and administer medical therapy. (5.9) Embryo-Fetal Toxicity: May cause fetal harm. Advise females of potential risk to fetus and need for use of effective contraception. (5.10, 8.1, 8.3) Ovarian Failure: Advise females of the potential risk. (5.11, 8.3) Congestive Heart Failure (CHF): Discontinue Alymsys in patients who develop CHF. (5.12)" (xsd:string)

Superclasses (1)

'\'Alymsys_(Bevacizumab)_\''

Disjoints (8)

Adverse_Reactions_ALYMS, Contraindications_ALYMS, Dosage_and_Administration_ALYMS, Dosage_Forms_and_Strengths_ALYMS, Drug_Interactions_ALYMS, Indications_and_Usage_ALYMS, Use in Specific Populations ALYMS, Warnings_and_Precautions_ALYMS

OWL HTML inside